荣昌生物与艾伯维就RC148签署独家授权许可协议

Core Viewpoint - Rongchang Biopharma (09995) has signed an exclusive licensing agreement with AbbVie for RC148, a novel bispecific antibody targeting PD-1/VEGF, which will provide significant financial benefits to the company upon regulatory approval [1] Group 1 - The agreement grants AbbVie exclusive rights to develop, manufacture, and commercialize RC148 outside Greater China [1] - Upon regulatory approval, the company will receive an upfront payment of $650 million [1] - The company is eligible for up to $4.95 billion in milestone payments related to development, regulatory, and commercialization achievements [1] Group 2 - The agreement includes tiered royalties based on net sales outside Greater China, which are expected to be in double digits [1] - The total milestone payment amount is subject to certain conditions, leading to uncertainty regarding the final achievable amount [1]